In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii-Reference-Cited by-同舟云学术

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Abdul-Mutakabbir Jacinda C.¹,Nguyen Logan¹,Maassen Philip T.¹,Stamper Kyle C.¹,Kebriaei Razieh¹,Kaye Keith S.²,Castanheira Mariana³^ORCID,Rybak Michael J.¹⁴⁵^ORCID

Affiliation:

1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA

2. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

3. JMI Laboratories, North Liberty, Iowa, USA

4. Division of Infectious Diseases, Department of Medicine, School of Medicine, Wayne State University, Detroit, Michigan, USA

5. Department of Pharmacy Services, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA

Abstract

Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii . Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02646-20

Reference24 articles.

1. Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group

2. Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections

3. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010

4. Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study

5. Carbapenem-resistantAcinetobacter baumannii: epidemiology, surveillance and management

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint;Journal of Global Antimicrobial Resistance;2024-09

2. Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant Acinetobacter spp.;Microbiology Spectrum;2024-08-20

3. Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria;Cells;2024-08-06

4. Lacticaseibacillus rhamnosus CRL 2244 secreted metabolites display killing and antibiotic synergistic activity against multi-drug resistant pathogens;PLOS ONE;2024-06-28

5. Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistantAcinetobacterspp;2024-03-06